Ajuster la taille de l'écran
Resize out
Resize in
Resize Réinitialiser
Done Fin
CureVac - Ingmar Hoerr, CEO

CureVac - Ingmar Hoerr, CEO

Vue 1,215 fois

Je ne suis pas un Robot

8.1
Merci, votre vote a été enregistré et sera visible bientôt.
Oui
Non
Description de la vidéo

CureVac, a clinical stage biopharmaceutical company from Tübingen, Germany, is pioneering the field of mRNA-based technology platforms for medical purposes with which mRNA is specifically optimised and formulated. Since 2000 the company develops novel mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases – both under the brand RNActive®. CureVac has successfully established the first GMP (good manufacturing practice) facility worldwide for the manufacture of RNA and mRNA and has pioneered mRNA-based drugs in clinical studies.

Commentaires